ARIETIS CORPORATION

Company Information
Address 650 ALBANY ST 130
BOSTON, MA, 02118-2518


Information

DUNS: 783349058

# of Employees: N/A


Ownership Information

Hubzone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Bactericidal antibiotic for Vancomycin Resistant Enterococci

    Amount: $2,469,884.00

    DESCRIPTION provided by applicant The goal of the project is to develop a therapeutic against vancomycin resistant enterococcus VRE These infections are a serious health concern because antibiot ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  2. Antibiotics for Recalcitrant Infection

    Amount: $3,000,000.00

    DESCRIPTION provided by applicant The goal of the project is to develop a therapeutic capable of sterilizing recalcitrant chronic infections such as deep seated abscess osteomyelitis endocarditis ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  3. Antibiotics for Recalcitrant Infection

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): The goal of the project is to develop a therapeutic capable of sterilizing recalcitrant chronic infections such as deep-seated abscess, osteomyelitis, endocarditis ...

    SBIRPhase I2014Department of Health and Human Services
  4. Narrow-spectrum Agents Acting against Helicobacter pylori

    Amount: $3,000,000.00

    DESCRIPTION provided by applicant The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori the causative agent of peptic ulcer and gastric carcinoma Roughly ...

    SBIRPhase II2013Department of Health and Human Services
  5. Compounds to treat Helicobacter pylori infection

    Amount: $585,967.00

    DESCRIPTION (provided by applicant): The goal of this project is to discover lead compounds acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. ...

    SBIRPhase I2012Department of Health and Human Services
  6. Narrow-spectrum Agents Acting against Helicobacter pylori

    Amount: $297,456.00

    DESCRIPTION (provided by applicant): The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Ro ...

    SBIRPhase I2012Department of Health and Human Services
  7. 2-adamantanamine Based Therapeutic for Recurrent Oropharyngeal Candidiasis

    Amount: $598,147.00

    DESCRIPTION (provided by applicant): The goal of this Phase I project is to evaluate 2-adamantanamine compounds as a potential therapeutic to treat recurrent oropharyngeal candidiasis (OPC) in HIV pat ...

    SBIRPhase I2010Department of Health and Human Services
  8. Therapy Against Recalcitrant C. albicans Infection

    Amount: $2,984,770.00

    DESCRIPTION (provided by applicant): One of the important unresolved problems in fungal antimicrobial chemotherapy is the ineffectiveness of existing therapeutics against cells that do no exist in a r ...

    SBIRPhase II2010Department of Health and Human Services
  9. THERAPY AGAINST RECALCITRANT C. albicans INFECTION

    Amount: $599,243.00

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop an effective therapy against relapsing vaginosis caused by Candida albicans. The disease occurs in 8-9% of all wom ...

    SBIRPhase I2008Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government